Original Literature | Model OverView |
---|---|
Publication
Title
Toll-like receptors: novel pharmacological targets for the treatment ofneurological diseases.
Affiliation
Department of Molecular Microbiology and Immunology, L220, Oregon Health andSciences University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA.marshb@ohsu.edu
Abstract
Toll-like receptors (TLRs) are a family of evolutionarily conserved moleculesthat directly detect pathogen invasion or tissue damage and initiate abiological response. TLRs can signal through two primary intracellular pathwaysand as such can induce either immuno-stimulatory or immuno-modulatory molecules.Both sides of this twin-edged sword are being examined for their therapeuticpotential in combating neurological disease. The immuno-stimulatory propertiesof TLRs are being used to generate tumor-specific immune responses to CNS tumorswhile the immuno-modulatory properties are being used to suppress damaginginflammatory responses to stroke. Recently, a third component of TLR signalinghas begun to emerge--that of direct neuroprotection. Hence, the TLRs offer noveltargets for the treatment of neurological disease.
PMID
17974478
|
Entity
IkappaB-alpha
--
MO000000233
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m199
10
infinite
0
InterPro | IPR002110 |
TRANSPATH | MO000000233 |
--
TLR3
--
MO000019398
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m3965
10
infinite
0
InterPro | IPR000157 |
TRANSPATH | MO000019398 |
--
dsRNA:TLR3
--
MO000041446
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m19314
10
infinite
0
TRANSPATH | MO000041446 |
--
--
e1
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane
--
--
--
csml-variable:Double
m1
0
infinite
0
--
--
e10
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytosol
--
--
--
csml-variable:Double
m10
0
infinite
0
--
csml-variable:Double
m11
0
infinite
0
--
ssRNA: TLR7
--
e12
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m12
0
infinite
0
--
CpG DNA
--
e13
cso30:c:Dna
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m13
0
infinite
0
--
CpG DNA: TLR9
--
e14
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m14
0
infinite
0
--
csml-variable:Double
m15
0
infinite
0
--
TLR ligand: TLR
--
e16
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m16
0
infinite
0
--
TLR ligand: TLR: MyD88: TIRAP: MAL
--
e17
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m17
0
infinite
0
--
TLT ligand: TLR: TRAM: TRIF
--
e18
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m18
0
infinite
0
--
--
e2
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m2
0
infinite
0
--
TLR ligand: TLR: MyD88: TIRAP: MAL: IRAK1: IRAK-4
--
e20
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m20
0
infinite
0
--
dsRNA:TLR3: TRIF
--
e21
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m21
0
infinite
0
--
TLR ligand: TLR: MyD88: TIRAP: MAL: IRAK1: IRAK-4: TRAF6
--
e22
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m22
0
infinite
0
--
IKK-alpha:IKK-beta:IKK-gamma
--
e24
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m24
10
infinite
0
TRANSPATH | MO000016661 |
--
IKK-alpha:IKK-beta:IKK-gamma {activated}
--
e25
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m25
10
infinite
0
TRANSPATH | MO000016661 |
--
NF-kappaB {activated}
--
e27
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m28
10
infinite
0
TRANSPATH | MO000000058 |
--
NF-kappaB {nucleus}
--
e28
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m29
10
infinite
0
TRANSPATH | MO000000058 |
--
dsRNA:TLR3: TRIF: IKK-i: TBK1: NAP1
--
e29
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m30
0
infinite
0
--
--
e3
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
--
csml-variable:Double
m3
0
infinite
0
--
csml-variable:Double
m31
10
infinite
0
Affymetrix | 1452196_a_at |
Ensembl | ENSMUSG00000027002 |
MGD | Nckap1 |
Proteome | HumanPSD/Nckap1 |
RefSeq | NM_016965 |
TRANSPATH | MO000079906 |
Unigene | Mm.25203 |
UniProt | P28660 |
--
TRAF3 {activated}
--
e31
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m32
10
infinite
0
InterPro | IPR001841 |
TRANSPATH | MO000016963 |
--
dsRNA:TLR3: TRIF: IKK-i {p}: TBK1: NAP1
--
e32
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m33
0
infinite
0
--
IRF-3 {activated}
--
e33
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m34
10
infinite
0
InterPro | IPR008984 |
TRANSPATH | MO000007694 |
--
imiquimod
--
e36
cso30:c:SmallMolecule
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m37
0
infinite
0
--
imiquimod: TLR7
--
e37
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m38
0
infinite
0
--
endigenous RNA
--
e38
cso30:c:Rna
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m39
0
infinite
0
--
endigenous RNA: TLR3
--
e39
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m40
0
infinite
0
--
--
e4
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m4
0
infinite
0
--
poly (I:C)
--
e40
cso30:c:SmallMolecule
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m41
0
infinite
0
--
poly (I:C): TLR3
--
e41
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m42
0
infinite
0
--
neurotrophin 4
--
e42
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m43
0
infinite
0
--
ephrin type B receptor 1
--
e43
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m44
0
infinite
0
--
PGN: TLR2
--
e5
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m5
0
infinite
0
--
--
e50
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelopeLumen
--
--
--
csml-variable:Double
m50
0
infinite
0
--
--
e51
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearPore
--
--
--
csml-variable:Double
m51
0
infinite
0
--
--
e52
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearInnerMembrane
--
--
--
csml-variable:Double
m52
0
infinite
0
--
--
e53
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearLumen
--
--
--
csml-variable:Double
m53
0
infinite
0
--
--
e54
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearOuterMembrane
--
--
--
csml-variable:Double
m54
0
infinite
0
--
--
e55
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleus
--
--
--
csml-variable:Double
m55
0
infinite
0
--
--
e56
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleoplasm
--
--
--
csml-variable:Double
m56
0
infinite
0
--
--
e57
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearBody
--
--
--
csml-variable:Double
m57
0
infinite
0
--
--
e58
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleolus
--
--
--
csml-variable:Double
m58
0
infinite
0
--
--
e59
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelope
--
--
--
csml-variable:Double
m59
0
infinite
0
--
LPS: TLR4
--
e6
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m6
0
infinite
0
--
--
e60
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Chromatin
--
--
--
csml-variable:Double
m60
0
infinite
0
--
--
e61
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearChromosome
--
--
--
csml-variable:Double
m61
0
infinite
0
--
--
e62
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearCentromere
--
--
--
csml-variable:Double
m62
0
infinite
0
--
--
e7
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell
--
--
--
csml-variable:Double
m7
0
infinite
0
--
--
e8
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell_WithoutCellWall_
--
--
--
csml-variable:Double
m8
0
infinite
0
--
--
e9
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytoplasm
--
--
--
csml-variable:Double
m9
0
infinite
0
--
p1
p1
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c1 : 1
stoichiometry:c2 : 1
stoichiometry:c3 : 1
m155701*m3964*0.1
nodelay
--
0
PMID: 17974478 The Toll-like receptors, so-called because of their homology to the Drosophila Toll receptor, were first characterized in mammals by their ability to recognize pathogen-associated molecules such as the bacterial cell wall components peptidoglycan (TLR2) and lipopolysaccharide (TLR4), as well as dsRNA (TLR3), ssRNA (TLR7), and nonmethylated Cytosine-Guanosine (CpG) DNA (TLR9).
p10
p10
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c32 : 1
stoichiometry:c33 : 1
stoichiometry:c34 : 1
m19314*m18998*0.1
nodelay
--
0
--
p11
p11
cso30:i:ME_Binding
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c35 : 1
stoichiometry:c36 : 1
stoichiometry:c37 : 1
m20*m183*0.1
nodelay
--
0
PMID: 17974478 Recruitment of MyD88 to the activated receptor initiates formation of the IL-1 receptor associated kinase (IRAK) complex resulting in phosphorylation of IKKalpha/bbeta, activation of the transcription factors NFkappaB, AP1, IRF1, and IRF7, and generation of the pro-inflammatory cytokines IL-6 and TNFalpha.
p12
p12
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c38 : 1
stoichiometry:c39 : 1
stoichiometry:c40 : 1
m22*m1573*0.1
nodelay
--
0
PMID: 17974478 Recruitment of MyD88 to the activated receptor initiates formation of the IL-1 receptor associated kinase (IRAK) complex resulting in phosphorylation of IKKalpha/bbeta, activation of the transcription factors NFkappaB, AP1, IRF1, and IRF7, and generation of the pro-inflammatory cytokines IL-6 and TNFalpha.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c41 : 1
stoichiometry:c42 : 1
stoichiometry:c43 : 1
m23*m24*0.1
nodelay
--
0
PMID: 17974478 Recruitment of MyD88 to the activated receptor initiates formation of the IL-1 receptor associated kinase (IRAK) complex resulting in phosphorylation of IKKalpha/bbeta, activation of the transcription factors NFkappaB, AP1, IRF1, and IRF7, and generation of the pro-inflammatory cytokines IL-6 and TNFalpha.
p14
p14
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c44 : 1
stoichiometry:c45 : 1
stoichiometry:c46 : 1
m25*m199*0.1
nodelay
--
0
PMID: 17974478 Recruitment of MyD88 to the activated receptor initiates formation of the IL-1 receptor associated kinase (IRAK) complex resulting in phosphorylation of IKKalpha/bbeta, activation of the transcription factors NFkappaB, AP1, IRF1, and IRF7, and generation of the pro-inflammatory cytokines IL-6 and TNFalpha.
p15
p15
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c47 : 1
stoichiometry:c48 : 1
stoichiometry:c49 : 1
m26*m27*0.1
nodelay
--
0
PMID: 17974478 Recruitment of MyD88 to the activated receptor initiates formation of the IL-1 receptor associated kinase (IRAK) complex resulting in phosphorylation of IKKalpha/bbeta, activation of the transcription factors NFkappaB, AP1, IRF1, and IRF7, and generation of the pro-inflammatory cytokines IL-6 and TNFalpha.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c50 : 1
stoichiometry:c51 : 1
m28*0.1
nodelay
--
0
PMID: 17974478 Recruitment of MyD88 to the activated receptor initiates formation of the IL-1 receptor associated kinase (IRAK) complex resulting in phosphorylation of IKKalpha/bbeta, activation of the transcription factors NFkappaB, AP1, IRF1, and IRF7, and generation of the pro-inflammatory cytokines IL-6 and TNFalpha.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c53 : 1
stoichiometry:c55 : 1
m29*0.1
nodelay
--
0
PMID: 17974478 Recruitment of MyD88 to the activated receptor initiates formation of the IL-1 receptor associated kinase (IRAK) complex resulting in phosphorylation of IKKalpha/bbeta, activation of the transcription factors NFkappaB, AP1, IRF1, and IRF7, and generation of the pro-inflammatory cytokines IL-6 and TNFalpha.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c52 : 1
stoichiometry:c54 : 1
m29*0.1
nodelay
--
0
PMID: 17974478 Recruitment of MyD88 to the activated receptor initiates formation of the IL-1 receptor associated kinase (IRAK) complex resulting in phosphorylation of IKKalpha/bbeta, activation of the transcription factors NFkappaB, AP1, IRF1, and IRF7, and generation of the pro-inflammatory cytokines IL-6 and TNFalpha.
p19
p19
cso30:i:ME_Binding
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c56 : 1
stoichiometry:c57 : 1
stoichiometry:c58 : 1
stoichiometry:c60 : 1
stoichiometry:c59 : 1
m21*m1599*m3902*m31*0.1
nodelay
--
0
PMID: 17974478 TLR3, on the other hand, signals through the MyD88 independent pathway, initiated by the TRIF adaptor molecule.
p2
p2
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c4 : 1
stoichiometry:c6 : 1
stoichiometry:c5 : 1
m3965*m119368*0.1
nodelay
--
0
PMID: 17974478 The Toll-like receptors, so-called because of their homology to the Drosophila Toll receptor, were first characterized in mammals by their ability to recognize pathogen-associated molecules such as the bacterial cell wall components peptidoglycan (TLR2) and lipopolysaccharide (TLR4), as well as dsRNA (TLR3), ssRNA (TLR7), and nonmethylated Cytosine-Guanosine (CpG) DNA (TLR9).
p20
p20
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c62 : 1
stoichiometry:c67 : 1
stoichiometry:c63 : 1
m1872*m33*0.1
nodelay
--
0
PMID: 17974478 Recruitment of TRIF to the receptor initiates phosphorylation of IKKe, which activates the transcription factors IRF3 and IRF7.
p21
p21
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c64 : 1
stoichiometry:c66 : 1
stoichiometry:c68 : 1
m32*m977*0.1
nodelay
--
0
PMID: 17974478 Recruitment of TRIF to the receptor initiates phosphorylation of IKKe, which activates the transcription factors IRF3 and IRF7.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c69 : 1
stoichiometry:c70 : 1
m34*0.1
nodelay
--
0
PMID: 17974478 Recruitment of TRIF to the receptor initiates phosphorylation of IKKe, which activates the transcription factors IRF3 and IRF7.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c61 : 1
stoichiometry:c65 : 1
m30*0.1
nodelay
--
0
PMID: 17974478 Recruitment of TRIF to the receptor initiates phosphorylation of IKKe, which activates the transcription factors IRF3 and IRF7.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c72 : 1
stoichiometry:c71 : 1
m35*0.1
nodelay
--
0
PMID: 17974478 Recruitment of TRIF to the receptor initiates phosphorylation of IKKe, which activates the transcription factors IRF3 and IRF7.
p25
p25
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c73 : 1
stoichiometry:c75 : 1
stoichiometry:c74 : 1
m980*m32*0.1
nodelay
--
0
PMID: 17974478 Recruitment of TRIF to the receptor initiates phosphorylation of IKKe, which activates the transcription factors IRF3 and IRF7.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c76 : 1
stoichiometry:c77 : 1
stoichiometry:c78 : 1
m37*m19940*0.1
nodelay
--
0
PMID: 17974478 One particularly attractive candidate for cancer immunotherapy is imiquimod, a synthetic TLR7 agonist that has been given FDA approval as a topical treatment for HSV-2 lesions.
p27
p27
cso30:i:ME_Binding
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c79 : 1
stoichiometry:c80 : 1
stoichiometry:c81 : 1
m3965*m39*0.1
nodelay
--
0
PMID: 17974478, 14729660 TLR3 detects viral dsRNA and can be activated by endogenous RNA released from necrotic cells.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c86 : 1
stoichiometry:c82 : 1
m42*0.1
nodelay
--
0
PMID: 17974478, 17085778, 15356140, 17061254 Microglia, neurons and astrocytes all produce IFNbeta upon stimulation with the synthetic TLR3 agonist polyinosinic-polycytidylic acid (poly(I:C)).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c83 : 1
stoichiometry:c84 : 1
stoichiometry:c85 : 1
m3965*m41*0.1
nodelay
--
0
PMID: 17974478, 17085778, 15356140, 17061254 Microglia, neurons and astrocytes all produce IFNbeta upon stimulation with the synthetic TLR3 agonist polyinosinic-polycytidylic acid (poly(I:C)). PMID: 17974478 TLR3 offers substantial promise as a novel therapeutic target in neuroprotection against CNS-related injury.
p3
p3
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c7 : 1
stoichiometry:c8 : 1
stoichiometry:c9 : 1
m155666*m3961*0.1
nodelay
--
0
PMID: 17974478 The Toll-like receptors, so-called because of their homology to the Drosophila Toll receptor, were first characterized in mammals by their ability to recognize pathogen-associated molecules such as the bacterial cell wall components peptidoglycan (TLR2) and lipopolysaccharide (TLR4), as well as dsRNA (TLR3), ssRNA (TLR7), and nonmethylated Cytosine-Guanosine (CpG) DNA (TLR9).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c91 : 1
stoichiometry:c87 : 1
m42*0.1
nodelay
--
0
PMID: 17974478 Astrocytes isolated from post mortem human adult subjects and stimulated with poly(I:C) induce the expression of multiple neuroprotective molecules (BDNF, neurotrophin 4, pleiotrophin, ephrin type B receptor1, TGFb2) and anti-inflammatory cytokines (IL-9, IL-10, IL-11).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c92 : 1
stoichiometry:c88 : 1
m42*0.1
nodelay
--
0
PMID: 17974478 Astrocytes isolated from post mortem human adult subjects and stimulated with poly(I:C) induce the expression of multiple neuroprotective molecules (BDNF, neurotrophin 4, pleiotrophin, ephrin type B receptor1, TGFb2) and anti-inflammatory cytokines (IL-9, IL-10, IL-11).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c93 : 1
stoichiometry:c89 : 1
m42*0.1
nodelay
--
0
PMID: 17974478 Astrocytes isolated from post mortem human adult subjects and stimulated with poly(I:C) induce the expression of multiple neuroprotective molecules (BDNF, neurotrophin 4, pleiotrophin, ephrin type B receptor1, TGFb2) and anti-inflammatory cytokines (IL-9, IL-10, IL-11).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c94 : 1
stoichiometry:c90 : 1
m42*0.1
nodelay
--
0
PMID: 17974478 Astrocytes isolated from post mortem human adult subjects and stimulated with poly(I:C) induce the expression of multiple neuroprotective molecules (BDNF, neurotrophin 4, pleiotrophin, ephrin type B receptor1, TGFb2) and anti-inflammatory cytokines (IL-9, IL-10, IL-11).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c95 : 1
stoichiometry:c96 : 1
m42*0.1
nodelay
--
0
PMID: 17974478 Astrocytes isolated from post mortem human adult subjects and stimulated with poly(I:C) induce the expression of multiple neuroprotective molecules (BDNF, neurotrophin 4, pleiotrophin, ephrin type B receptor1, TGFb2) and anti-inflammatory cytokines (IL-9, IL-10, IL-11).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c97 : 1
stoichiometry:c100 : 1
m42*0.1
nodelay
--
0
PMID: 17974478 Astrocytes isolated from post mortem human adult subjects and stimulated with poly(I:C) induce the expression of multiple neuroprotective molecules (BDNF, neurotrophin 4, pleiotrophin, ephrin type B receptor1, TGFb2) and anti-inflammatory cytokines (IL-9, IL-10, IL-11).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c98 : 1
stoichiometry:c101 : 1
m42*0.1
nodelay
--
0
PMID: 17974478 Astrocytes isolated from post mortem human adult subjects and stimulated with poly(I:C) induce the expression of multiple neuroprotective molecules (BDNF, neurotrophin 4, pleiotrophin, ephrin type B receptor1, TGFb2) and anti-inflammatory cytokines (IL-9, IL-10, IL-11).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c99 : 1
stoichiometry:c102 : 1
m42*0.1
nodelay
--
0
PMID: 17974478 Astrocytes isolated from post mortem human adult subjects and stimulated with poly(I:C) induce the expression of multiple neuroprotective molecules (BDNF, neurotrophin 4, pleiotrophin, ephrin type B receptor1, TGFb2) and anti-inflammatory cytokines (IL-9, IL-10, IL-11).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c10 : 1
stoichiometry:c11 : 1
stoichiometry:c12 : 1
m11*m19940*0.1
nodelay
--
0
PMID: 17974478 The Toll-like receptors, so-called because of their homology to the Drosophila Toll receptor, were first characterized in mammals by their ability to recognize pathogen-associated molecules such as the bacterial cell wall components peptidoglycan (TLR2) and lipopolysaccharide (TLR4), as well as dsRNA (TLR3), ssRNA (TLR7), and nonmethylated Cytosine-Guanosine (CpG) DNA (TLR9).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c13 : 1
stoichiometry:c14 : 1
stoichiometry:c15 : 1
m13*m19828*0.1
nodelay
--
0
PMID: 17974478 The Toll-like receptors, so-called because of their homology to the Drosophila Toll receptor, were first characterized in mammals by their ability to recognize pathogen-associated molecules such as the bacterial cell wall components peptidoglycan (TLR2) and lipopolysaccharide (TLR4), as well as dsRNA (TLR3), ssRNA (TLR7), and nonmethylated Cytosine-Guanosine (CpG) DNA (TLR9). PMID: 17974478 Perhaps the most promising TLR ligands in the fight against cancers of the CNS are the TLR9 agonists, nonmethylated CpG oligodeoxynucleotides.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c16 : 1
stoichiometry:c17 : 1
stoichiometry:c18 : 1
m3962*m15*0.1
nodelay
--
0
PMID: 17974478 Each TLR family member, with the exception of TLR3, signals through the MyD88 dependent pathway, initiated by the MyD88 adaptor protein.
p7
p7
cso30:i:ME_Binding
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c19 : 1
stoichiometry:c20 : 1
stoichiometry:c21 : 1
stoichiometry:c22 : 1
stoichiometry:c23 : 1
m1572*m6810*m43675*m16*0.1
nodelay
--
0
PMID: 17974478 Each TLR family member, with the exception of TLR3, signals through the MyD88 dependent pathway, initiated by the MyD88 adaptor protein.
p8
p8
cso30:i:ME_Binding
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c24 : 1
stoichiometry:c25 : 1
stoichiometry:c26 : 1
stoichiometry:c27 : 1
m19005*m16*m18998*0.1
nodelay
--
0
--
p9
p9
cso30:i:ME_Binding
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c28 : 1
stoichiometry:c29 : 1
stoichiometry:c30 : 1
stoichiometry:c31 : 1
m17*m19*m17258*0.1
nodelay
--
0
PMID: 17974478 Recruitment of MyD88 to the activated receptor initiates formation of the IL-1 receptor associated kinase (IRAK) complex resulting in phosphorylation of IKKalpha/bbeta, activation of the transcription factors NFkappaB, AP1, IRF1, and IRF7, and generation of the pro-inflammatory cytokines IL-6 and TNFalpha.
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--